14.15

2.35% -0.34

After Hours: 14.15

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $14.15, with a volume of 637.37K. It is down -2.35% in the last 24 hours and up +4.58% over the past month. Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Previous Close:

$14.49

Open:

$14.21

24h Volume:

637.37K

Relative Volume:

0.81

Market Cap:

$922.23M

Revenue:

Net Income/Loss:

$-119.67M

P/E Ratio:

-5.1832

EPS:

-2.73

Net Cash Flow:

$-97.30M

1W Performance:

-0.77%

1M Performance:

+4.58%

6M Performance:

+37.38%

1Y Performance:

+14.21%

1-Day Range:

$14.01

$14.49

1-Week Range:

$13.41

$15.15

52-Week Range:

$8.241

$18.38

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER ROAD, RADNOR

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	14.15	944.39M	0	-119.67M	-97.30M	-2.73
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

Jul 31, 2025

Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛

Jul 31, 2025

Jul 30, 2025

Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com India

Jul 30, 2025

Jul 28, 2025

Aldosterone Synthase Inhibitors Market is evolving rapidly - openPR.com

Jul 28, 2025

What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive stock market forecasts - jammulinksnews.com

Jul 28, 2025

How volatile is Mineralys Therapeutics Inc. stock compared to the marketUnlock your trading potential today - jammulinksnews.com

Jul 28, 2025

Intrinsic Value of Mineralys Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAccurate Technical Trend Reversal Picks Detected - metal.it

Jul 28, 2025

Will Mineralys Therapeutics Inc. stock split in the near futureTrend Analysis for Safer Trades Gains Popularity - metal.it

Jul 28, 2025

Is Mineralys Therapeutics Inc. a growth stock or a value stockExceptional market positioning - jammulinksnews.com

Jul 28, 2025

What are Mineralys Therapeutics Inc. company’s key revenue driversAchieve breakthrough financial results - jammulinksnews.com

Jul 28, 2025

How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Dynamic capital growth - jammulinksnews.com

Jul 28, 2025

Why is Mineralys Therapeutics Inc. stock attracting strong analyst attentionOutstanding trading profits - jammulinksnews.com

Jul 28, 2025

Jul 27, 2025

What are the latest earnings results for Mineralys Therapeutics Inc.Get real-time updates on market trends - jammulinksnews.com

Jul 27, 2025

What are the technical indicators suggesting about Mineralys Therapeutics Inc.Unrivaled growth potential - jammulinksnews.com

Jul 27, 2025

Is Mineralys Therapeutics Inc. stock overvalued or undervaluedCapitalize on market shifts with expert advice - jammulinksnews.com

Jul 27, 2025

What is Mineralys Therapeutics Inc. company’s growth strategyPowerful market insights - jammulinksnews.com

Jul 27, 2025

How strong is Mineralys Therapeutics Inc. company’s balance sheetBuild a portfolio that grows with the market - jammulinksnews.com

Jul 27, 2025

What makes Mineralys Therapeutics Inc. stock price move sharplyFree Investment Group - metal.it

Jul 27, 2025

Jul 25, 2025

Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? - Zacks Investment Research

Jul 25, 2025

What analysts say about Mineralys Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia

Jul 25, 2025